End Stage Renal Disease Clinical Trial
— MATILDAOfficial title:
MAgic Touch™ Intervention Leap for Dialysis Access (MATILDA) Trial
NCT number | NCT04698512 |
Other study ID # | MATILDA |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 21, 2019 |
Est. completion date | January 30, 2021 |
Verified date | March 2021 |
Source | Singapore General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
For patients with End Stage Renal Failure (ESRF), the surgical creation of an Autogenous Arteriovenous Fistula (AVF) or Autogenous Arteriovenous Graft (AVG) is the recognised standard for providing vascular access. A functioning dialysis vascular access is essential to facilitate hemodialysis (HD) treatment. Advantages include improved hemodialysis initiation time, improved dialysis quality, better maintenance of accesses and generally, better outcomes in patients. Unfortunately almost 50% of AVF and AVG fail after a median lifetime of 3 to 7 years and 12 to 18 months respectively. Vascular access dysfunction is a major cause of morbidity and hospitalisation for ESRF patients, costing the healthcare system USD 18 million globally. Venous stenosis and scarring are caused by trauma from surgical access creation when the circuit comes arterialized and from repeated percutaneous punctures from subsequent hemodialysis. This study is performed to evaluate Sirolimus-coated balloon efficacy and safety using MagicTouch™ Drug coated balloon catheter (Concept Medical Inc, Tampa, FL, US) on AVF patency with de novo and recurrent stenosis.
Status | Completed |
Enrollment | 35 |
Est. completion date | January 30, 2021 |
Est. primary completion date | January 16, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 90 Years |
Eligibility | Inclusion Criteria: - Informed consent was obtained - Patient aged = 21 and = 90 years - Native AVF was created more than 2 months prior to index procedure and had undergone 10 or more haemodialysis sessions utilizing two needles - Target lesion location had to be located between the anastomoses to the axillary-subclavian vein junction, as defined by insertion of the cephalic vein - On initial fistulogram, target lesions stenosis had to be =50 on angiographic assessment and in keeping with the clinical indicator for intervention - Stenosis had to <12cm in length (to allow for potential treatment with one SCB (length 15cm) only - Stenosis had to be initially treated successfully with a high-pressure plain balloon prior to SCB treatment as defined by:- (A) no clinically significant dissection (flow limiting) (B) no extravasation requiring treatment/stenting (C) residual stenosis =30% by angiographic measurement (D) Ability to completely efface the lesion waist using the pre-dilation balloon - No more than one additional ("nontarget") lesion in the access circuit that had to be also successfully treated (=30% residual stenosis) before drug elution. Separate lesion was defined by at least 3cm in distance from the target lesion. - Reference vessel diameter 5mm-8mm Exclusion Criteria: - Women who were preganant, lactating, or planning on becoming pregnant during the study - Subject had more than 2 lesions in the access circuit - Subject had a secondary non-target lesion that could not be successfully treated - Sepsis or active infection - Asymptomatic target lesions - A thrombosed access or an access with thrombosis treated = 30 days prior to index procedure - Surgical revision of the access site performed, planned or expected = 3months before or after the index procedure - Patients who were taking immunosuppressive therapy or are routinely taking =15 mg prednisone per day - Currently participating in another investigational drug, biologic, or device study involving Sirolimus or paclitaxel - Contraindication to Aspirin or Clopidogrel usage - Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, or language barrier such that the subject is unable to give informed consent - Uncooperative attitude or potential for non-compliance with the requirements of the protocol making study participation impractical - Where final angioplasty treatment requires a stent or drug eluting balloon >8mm in diameter - Metastatic cancer or terminal medical condition - Blood coagulation disorders - Limited life expectancy (<12 months) - Allergy or other know contraindication to iodinated media contrast, heparin, or Sirolimus |
Country | Name | City | State |
---|---|---|---|
Singapore | Singapore General Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
Singapore General Hospital |
Singapore,
Lee T, Roy-Chaudhury P. Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis. 2009 Sep;16(5):329-38. doi: 10.1053/j.ackd.2009.06.009. Review. — View Citation
Pantelias K, Grapsa E. Vascular access today. World J Nephrol. 2012 Jun 6;1(3):69-78. doi: 10.5527/wjn.v1.i3.69. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Target Lesion Primary Patency | No need for clinically driven reintervention of target lesion, no access thrombosis and no significant restenosis (lumen diameter <2.7mm) on duplex ultrasound | 3-months post op | |
Primary | Target Lesion Primary Patency | No need for clinically driven reintervention of target lesion, no access thrombosis and no significant restenosis (lumen diameter <2.7mm) on duplex ultrasound | 6-months post op | |
Primary | Freedom from localised or systemic serious adverse events | Include life-threatening events or those resulting in death, requiring hospitalisation, resulting in permanent disability, or requiring intervention to prevent permanent impairment | 30 days post-op | |
Secondary | Access circuit patency | Lack of stenosis in any region of the AVF circuit requiring intervention | 3 and 6 months post op | |
Secondary | Procedural success | Defined as technical success with at least one indicator of hemodynamic or clinical success. I.e. no conduit rupture during any of the procedures requiring bailout stenting. | Day of operation | |
Secondary | Primary assisted patency | Lack of access circuit thrombosis requiring thrombolysis | 3 and 6 months post op | |
Secondary | Number of open bypass revision surgery required to maintain access circuit primary patency | 3 and 6 months post op | ||
Secondary | Secondary access patency | Lack of dialysis access abandonment | 3 and 6 months post-op | |
Secondary | Number of interventions required to maintain access circuit primary patency | 3 and 6 months post-op | ||
Secondary | Event of mortality | 6 months post-op |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04076488 -
Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases
|
N/A | |
Completed |
NCT03289650 -
Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
|
Phase 3 | |
Completed |
NCT04042324 -
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01242904 -
Use of a Bimodal Solution for Peritoneal Dialysis
|
Phase 2 | |
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT03257410 -
Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A | |
Withdrawn |
NCT02130817 -
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
|
Phase 4 | |
Completed |
NCT05540457 -
Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
|
N/A | |
Not yet recruiting |
NCT04900610 -
The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
|
N/A | |
Recruiting |
NCT02176434 -
Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease
|
N/A | |
Active, not recruiting |
NCT02581449 -
Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis
|
Phase 2 | |
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Completed |
NCT02215655 -
Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence
|
N/A | |
Completed |
NCT02832466 -
Quantifying the Deterioration of Physical Function in Renal Patients
|
N/A | |
Completed |
NCT02832440 -
Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis
|
N/A | |
Completed |
NCT02830490 -
Reliability of Functional Measures in Hemodialysis Patient.
|
N/A | |
Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A |